LYRA Lyra Therapeutics, Inc.
USHealthcareAs of 2026-03-18 09:30
Why LYRA matters now
Lyra Therapeutics, Inc. (LYRA) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.44 with -11.98% on the session and $781.1K in market capitalization; recent performance reads 1-month -11.98% and YTD -85.71%.
The latest financial table shown here is Q4 2025, with revenue of $7.0K, net income of $-7.0M, and EPS of $-9.60. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3709.4%.
The latest indexable market news headline is "Lyra Therapeutics, Inc. Announces Intention to Voluntarily File Form 25 for Delisting from Nasdaq and Subsequent Deregistration with the SEC" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $0.50; recent insider activity includes Smith W Bradford filing D-Return. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-0.64
P/S
1.96
EV/EBITDA
-0.55
DCF Value
$-2.81
FCF Yield
-3709.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-7794.5%
Net Margin
-7266.1%
ROE
1211.1%
ROA
-80.1%
ROIC
-98.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $7.0K | $-7.0M | $-9.60 |
| FY 2025 | $398.0K | $-28.9M | $-18.62 |
| Q3 2025 | $25.0K | $-6.0M | $-3.38 |
| Q2 2025 | $183.0K | $-7.4M | $-5.51 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$0.50
Target (Median)
$0.50
Target Range
$0.50 - $0.50
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.69
Lyra Therapeutics, Inc. operates as a clinical-stage biotechnology company, primarily focused on the creation and commercialization of anti-inflammatory treatments for individuals suffering from chronic rhinosinusitis (CRS). The company's unique technological approach allows for the direct delivery of therapeutic agents to the targeted tissue, ensuring prolonged efficacy from a singular dose. Its pipeline features several promising candidates, including LYR-210, an anti-inflammatory implantable drug matrix currently in Phase III clinical trials for CRS. Additionally, LYR-220 is under development for CRS patients who have not responded to previous medical treatments and still require intervention for their symptoms. Lyra has forged a partnership with LianBio Inflammatory Limited to facilitate the development and market entry of LYR-210 throughout specific Asian regions, encompassing mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. Established in 2005, the company was initially known as 480 Biomedical, Inc. before adopting the name Lyra Therapeutics, Inc. in July 2018. Its corporate headquarters are located in Watertown, Massachusetts.